295.22
price up icon1.48%   4.31
after-market 시간 외 거래: 295.80 0.58 +0.20%
loading
전일 마감가:
$290.91
열려 있는:
$290.08
하루 거래량:
401.85K
Relative Volume:
0.76
시가총액:
$12.69B
수익:
$2.99B
순이익/손실:
$1.21B
주가수익비율:
11.78
EPS:
25.06
순현금흐름:
$1.13B
1주 성능:
+3.23%
1개월 성능:
-9.30%
6개월 성능:
-18.04%
1년 성능:
-6.89%
1일 변동 폭
Value
$290.08
$295.98
1주일 범위
Value
$282.42
$295.98
52주 변동 폭
Value
$266.98
$417.81

유나이티드 테라퓨틱스 Stock (UTHR) Company Profile

Name
명칭
United Therapeutics Corp
Name
전화
(301) 608-9292
Name
주소
1000 SPRING ST, SILVER SPRING, MD
Name
직원
1,305
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
UTHR's Discussions on Twitter

UTHR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
295.22 12.69B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
10.36 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.08 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.26 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.42 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.05 20.17B 16.54B -1.64B 749.00M -1.45

유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-02 개시 Cantor Fitzgerald Overweight
2025-04-25 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-04-21 업그레이드 BofA Securities Underperform → Neutral
2024-07-11 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-02-12 업그레이드 Goldman Sell → Neutral
2024-02-05 개시 Leerink Partners Outperform
2023-12-08 개시 Wells Fargo Overweight
2022-12-06 개시 UBS Buy
2022-12-05 개시 Goldman Sell
2022-10-11 개시 Morgan Stanley Overweight
2022-09-20 재확인 BofA Securities Underperform
2022-09-19 재개 Wedbush Outperform
2022-02-11 개시 BTIG Research Neutral
2021-07-14 업그레이드 Argus Hold → Buy
2021-04-26 재개 Credit Suisse Outperform
2021-02-01 업그레이드 H.C. Wainwright Neutral → Buy
2020-09-14 재개 JP Morgan Overweight
2020-06-25 재확인 H.C. Wainwright Neutral
2020-03-10 업그레이드 Jefferies Hold → Buy
2020-02-27 업그레이드 Cowen Market Perform → Outperform
2020-01-31 업그레이드 JP Morgan Neutral → Overweight
2019-12-03 개시 BofA/Merrill Underperform
2019-08-01 업그레이드 Jefferies Underperform → Hold
2019-08-01 업그레이드 Ladenburg Thalmann Neutral → Buy
2019-07-01 업그레이드 Credit Suisse Neutral → Outperform
2019-05-17 업그레이드 UBS Sell → Neutral
2019-05-09 업그레이드 Credit Suisse Underperform → Neutral
2018-10-12 업그레이드 Standpoint Research Hold → Buy
2018-08-08 다운그레이드 Credit Suisse Neutral → Underperform
2018-04-03 업그레이드 Credit Suisse Underperform → Neutral
2018-02-22 재확인 Barclays Underweight
2018-01-18 재개 Credit Suisse Underperform
2017-12-27 재확인 Wedbush Outperform
2017-04-27 재확인 Wedbush Outperform
2017-03-30 개시 UBS Sell
2017-03-16 개시 Credit Suisse Underperform
모두보기

유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스

pulisher
Jun 17, 2025

United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com

Jun 16, 2025
pulisher
Jun 15, 2025

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga

Jun 15, 2025
pulisher
Jun 11, 2025

United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News

Jun 10, 2025
pulisher
Jun 06, 2025

Treprostinil Saga Continues - JD Supra

Jun 06, 2025
pulisher
Jun 06, 2025

United Therapeutics president sells shares worth $3.7 million - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com

Jun 04, 2025
pulisher
Jun 03, 2025

United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 29, 2025

Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360

May 29, 2025
pulisher
May 29, 2025

United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 29, 2025
pulisher
May 29, 2025

Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo

May 29, 2025
pulisher
May 27, 2025

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga

May 27, 2025
pulisher
May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025
pulisher
May 26, 2025

Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com

May 26, 2025
pulisher
May 24, 2025

FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey

May 24, 2025
pulisher
May 24, 2025

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World

May 24, 2025
pulisher
May 23, 2025

FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World

May 23, 2025
pulisher
May 21, 2025

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals

May 21, 2025
pulisher
May 20, 2025

Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News

May 20, 2025
pulisher
May 15, 2025

Construction underway for new United Therapeutics facility in Stewartville - KTTC News

May 15, 2025
pulisher
May 14, 2025

Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin

May 14, 2025
pulisher
May 14, 2025

Interesting UTHR Put And Call Options For July 18th - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360

May 12, 2025
pulisher
May 12, 2025

Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025
pulisher
May 07, 2025

3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360

May 05, 2025
pulisher
May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025

유나이티드 테라퓨틱스 (UTHR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
MAHON PAUL A
EVP & GENERAL COUNSEL
Jun 26 '25
Sale
285.70
11,000
3,142,718
36,781
$129.40
price up icon 1.09%
drug_manufacturers_specialty_generic RDY
$14.88
price down icon 0.40%
$9.34
price up icon 1.74%
$14.72
price up icon 2.01%
$17.05
price up icon 2.46%
자본화:     |  볼륨(24시간):